Vial
FOXO4-DRI Vial 10mg
FOXO4-DRI senolytic research peptide, 10mg per vial.
Est. delivery
Also Known As: Proxofim, FOXO4-D-Retro-Inverso
FOXO4-DRI is also known as Proxofim or FOXO4-D-Retro-Inverso — names for the same D-retro-inverso peptide studied for its interference with the FOXO4-p53 interaction in senescent cells. For research use only.
Certificate of Analysis
Each batch is tested by an independent third-party laboratory for:
- Peptide identity verification
- Purity analysis via HPLC (≥99%)
- Microbial contaminant screening
- Heavy metal analysis
- Residual solvent testing
Reference Chemistry
Specification
- Composition
- FOXO4-DRI
- Presentation
- 10mg per vial, 3mL
- Format
- Vial
- Storage
- Cool, dry, out of direct sunlight; refrigerate after opening
CAS number, molecular formula and molecular weight for this compound are available on request, together with the batch certificate of analysis.
RESEARCH USE ONLY — not for human or animal consumption. Not for diagnostic or therapeutic use.
Description
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with the FOXO4-p53 interaction, supplied as a 10mg vial.
Research Background
FOXO4-DRI has been studied in preclinical senescence research for its proposed ability to selectively induce apoptosis in senescent cells by disrupting FOXO4-p53 binding.
This product is intended strictly for laboratory research purposes and is not for human consumption, clinical, diagnostic, or therapeutic use.
Ingredients & Dosage
| FOXO4-DRI | 10mg per vial |
Inactive ingredients / formulation base
| Mannitol | Bulking agent |
Amino Acid Sequence: D-retro-inverso FOXO4 peptide with cell-penetrating sequence
SKU: FXV0010MG
Shipping & Storage
Shipping: Every order ships 2-Day — free on orders $150+, $4.99 otherwise. Orders placed before 3 PM PT on a business day dispatch the same day, and delivery is typically 2 business days after dispatch.
Storage: Store in a cool, dry place. Refrigeration recommended after opening for optimal stability. Keep away from direct sunlight.
Regulatory Statement
For laboratory and research use only. Not for human or animal consumption. This product is sold exclusively to qualified researchers and licensed laboratories.
This product is not a drug, food, or cosmetic, and is not for diagnostic or therapeutic use. These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
A certificate of analysis (COA) is available for this product on request. Contact our team to request the batch COA.
Why Research Peptides
All comparisons reflect general industry practices. Stemcode products are intended solely for laboratory research and are not for human consumption.
The Research Standard
All comparisons reflect general industry practices. Stemcode products are intended solely for laboratory research and are not for human consumption.
Frequently Asked Questions
What is FOXO4-DRI?
FOXO4-DRI is a D-retro-inverso peptide designed to interfere with the interaction between FOXO4 and p53. It has been investigated in preclinical senescence research, where disrupting that interaction is studied as a way to trigger apoptosis in senescent cells. This product is a 10mg lyophilized vial intended for laboratory research use only.
What is in Stemcode's FOXO4-DRI vial?
Each vial contains 10mg of FOXO4-DRI as a lyophilized powder. Every batch is third-party lab tested for identity and purity, with results published in its Certificate of Analysis, and ships from within the United States.
Are there human trials on FOXO4-DRI?
No. The published FOXO4-DRI literature is preclinical — cell culture and animal models. There are no completed human clinical trials. This product is supplied strictly for in-vitro laboratory research and is not for human or animal use.
What dosing has been used in published FOXO4-DRI research?
The two most-cited in-vivo studies converge on the same regimen in mice. Baar et al. (Cell, 2017) administered FOXO4-DRI at 5 mg/kg intravenously on days 1, 3 and 5 — three doses, every other day — and also report intraperitoneal schedules of 3 × 5 mg/kg or 5 × 25 mg/kg/day. Zhang et al. (Aging, 2020) used 5 mg/kg intraperitoneally every other day for three administrations in 20-24 month old C57BL/6 mice. In-vitro work on human cells in the 2017 paper used 25 μM, given either once or as three consecutive 8.33 μM doses. These are published animal and cell-culture parameters reported for reference only. They are not a protocol, not a recommendation, and not applicable to humans — this product is for in-vitro laboratory research use only.
Is FOXO4-DRI the same as Proxofim?
Proxofim is an alternate name used for the same D-retro-inverso FOXO4 peptide studied in senescent-cell research. Both names refer to the same compound. For research use only.
Where can I buy FOXO4-DRI?
FOXO4-DRI is available to order directly from Stemcode for research use. Every batch is lab tested for purity with a published Certificate of Analysis and ships from within the United States.
How should FOXO4-DRI be stored?
As a lyophilized powder, store the sealed vial refrigerated at 2-8°C (36-46°F) and protect it from light and moisture. Once reconstituted, keep it refrigerated and use it within the timeframe your protocol specifies.
Is FOXO4-DRI for human use?
No. FOXO4-DRI and all Stemcode products are sold strictly for in-vitro laboratory and research use only. They are not for human or animal consumption.
